All In Biotech

Drug Trial Radar · NCT04486313

Trial to Evaluate Efficacy and Safety of Nitazoxanide in the Treatment of Mild or Moderate COVID-19

Phase 3, Randomized, Double-Blind, Placebo-Controlled, Trial to Evaluate Efficacy and Safety of Nitazoxanide in the Treatment of Mild or Moderate COVID-19

Last checked: Nov 20, 2026Latest source record: Mar 29, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 935 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

935

Actual

Start

Aug 13, 2020

Primary completion

Feb 8, 2021

Study completion Feb 8, 2021

Sponsor

Lead sponsor
Romark Laboratories L.C.Industry
Sponsor type
Industry
First posted
Jul 24, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years, up to 120 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Trial to Evaluate Efficacy and Safety of Nitazoxanide in the Treatment of Mild or Moderate COVID-19

Conditions

  • COVID-19

Interventions

  • NitazoxanideDrug

    Two nitazoxanide 300 mg tablets administered orally twice daily with food for 5 days

  • PlaceboDrug

    Two placebo tablets administered orally twice daily with food for 5 days

  • Vitamin Super B-ComplexDietary supplement

    Vitamin Super B-Complex administered orally twice daily to maintain the blind

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time to Sustained Clinical RecoveryTime frame: Up to 21 days

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Invesclinic US LLC

    Fort Lauderdale, Florida

  • RH Medical Urgent Care

    The Bronx, New York

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.